Cetuximab in treatment of metastatic colorectal cancer: final survival analyses and extended RAS data from the NORDIC-VII study
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The NORDIC-VII study is a randomised phase III trial of cetuximab plus continuous or intermittent fluorouracil, folinic acid, and oxaliplatin (Nordic FLOX) vs FLOX alone in first-line treatment of metastatic colorectal cancer. The present report presents an updated and final survival analysis with BRAF and extended RAS mutational status, 5 years after the primary analysis. METHODS: A total of 566 patients were included in the intention-to-treat (ITT) population of the NORDIC-VII study. Updated survival status was obtained from 176 patients who were alive in the primary survival analyses. Samples from 223 tumours previously found to be KRAS (exon 2) and BRAF (V600E) wild-type, were re-analysed for KRAS (exons 3 and 4) and NRAS (exons 2-4) mutations. RESULTS: Including the extended RAS analyses, RAS and BRAF mutational status was available from 457 patients (81% of the ITT population). RAS was mutated in 46% and BRAF in 12% of the tumours. RAS and BRAF, if mutated, were negative prognostic factors. The updated analyses confirmed the finding of the primary report that cetuximab did not provide any additional benefit when added to FLOX in patients with RAS/BRAF wild-type tumours, neither on progression-free nor overall survival. However, the outcomes in a subset of patients, which, after the first eight treatment cycles, received cetuximab alone, suggested a beneficial effect of cetuximab monotherapy. CONCLUSIONS: Adding cetuximab to Nordic FLOX did not provide any clinical benefit, but the data suggested an effect of cetuximab monotherapy in patients with RAS/BRAF wild-type tumours in the NORDIC-VII cohort. The data were compatible with a negative interaction between cetuximab and the Nordic FLOX chemotherapy backbone.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877 · cited 10×
“In view of the results of NORDIC-VII, together with the data from COIN and the New EPOC trials (Maughan et al, 2011; Primrose et al, 2014), as compared to trials where cetuximab was combined with irinotecan-based regimens (Van Cutsem et al, 2009), it may be discussed whether cetuximab and oxaliplatin are good partners.”
InfluentialK-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207
Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
Douillard, J.-Y., Oliner, K. S., Siena, S., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305275 · Cited by 2,263 · cited 2×
“Extended RAS analyses have demonstrated lack of response to EGFR antibodies also in patients with tumours harbouring other KRAS (exons 3 and 4) or NRAS mutations (Douillard et al, 2013; Bokemeyer et al, 2015; Van Cutsem et al, 2015).”
InfluentialRAF/RAS oncogenes and mismatch-repair status
Rajagopalan, H., Bardelli, A., Lengauer, C., Kinzler, K. W., Vogelstein, B., & Velculescu, V. E. (2002) · Nature · doi:10.1038/418934a · Cited by 1,224 · cited 1×
“As KRAS and BRAF mutations were considered to be mutually exclusive (Rajagopalan et al, 2002), tumour DNA from the remaining 223 KRAS (exon 2)/BRAF wild-type patients was analysed for the other KRAS mutations (in exons 3 and 4) and NRAS mutations (in exons 2, 3, and 4).”
Cremolini, C., Loupakis, F., Antoniotti, C., Lupi, C., Sensi, E., Lonardi, S., Mezi, S., Tomasello, G., Ronzoni, M., Zaniboni, A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00122-9 · Cited by 1,092 · cited 1×
“…2015; Van Cutsem et al, 2015), and patients with tumours harbouring RAS or BRAF mutations showed impaired outcomes compared to those with RAS/BRAF wild-type tumours, also in line with results reported from recent first-line chemotherapy trials in mCRC (Maughan et al, 2011; Cremolini et al, 2015).”
Van Cutsem, E., Lenz, H.-J., Köhne, C.-H., Heinemann, V., Tejpar, S., Melezínek, I., Beier, F., Stroh, C., Rougier, P., van Krieken, J. H., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.4812 · Cited by 789
Tejpar, S., Stintzing, S., Ciardiello, F., Tabernero, J., Van Cutsem, E., Beier, F., Esser, R., Lenz, H.-J., & Heinemann, V. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.3797 · Cited by 709 · cited 2×
“Recently, pooled data from two randomised phase III trials have emphasised that clinical benefit of cetuximab treatment is significantly higher in patients with left-sided colon and rectum tumours compared to right-sided (Tejpar et al, 2017).”
FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer
Bokemeyer, C., Köhne, C.-H., Ciardiello, F., Lenz, H.-J., Heinemann, V., Klinkhardt, U., Beier, F., Duecker, K., van Krieken, J. H., & Tejpar, S. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.04.007 · Cited by 256
Cited by
Cervantes, A., Adam, R., Roselló, S., Arnold, D., Normanno, N., Taïeb, J., Seligmann, J., De Baere, T., Osterlund, P., Yoshino, T., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2022.10.003 · Cited by 1,796
Self-citationBiomarker-guided therapy for colorectal cancer: strength in complexity
Sveen, A., Kopetz, S., & Lothe, R. A. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0241-1 · Cited by 320
An Update of Efficacy and Safety of Cetuximab in Metastatic Colorectal Cancer: A Narrative Review
Fornasier, G., Francescon, S., & Baldo, P. (2018) · Advances in Therapy · doi:10.1007/s12325-018-0791-0 · Cited by 134
Metadata
- Authors
- Guren, T. K., Thomsen, M., Kure, E. H., Sorbye, H., Glimelius, B., Pfeiffer, P., Österlund, P., Sigurdsson, F., Lothe, I. M. B., Dalsgaard, A. M., Skovlund, E., Christoffersen, T., & Tveit, K. M.
- Venue
- British Journal of Cancer
- Published
- 2017-04-11
- Volume
- 116
- Issue
- 10
- Pages
- 1271-1278
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2606308933
- Cited by
- 74
- References
- 9
- FWCI
- 3.02
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.